A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of
fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer
(NMIBC) patients with recurrent tumors and a prior history of low- or intermediate-risk NMIBC
tumors. Participants will receive pemigatinib for 4-6 weeks prior to standard of care
transurethral resection of bladder tumor (TURBT).
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins